New Sjögren's drug IBI355 enters human testing

NCT ID NCT06484855

Completed Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests an experimental drug called IBI355 in 30 adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. The main goal is to check the drug's safety and how the body processes it at different doses. Participants receive either IBI355 or a placebo by IV every 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI355 (an experimental drug given by IV infusion every 4 weeks)
What this could lead to: If successful, this could point toward a new treatment option to control Sjögren's syndrome symptoms and disease activity.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so it is primarily checking safety and dosing—not yet testing if the drug actually works. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SJÖGREN'S SYNDROME

Contacts and locations

Locations

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.